Skip to main content

Clifford Chance

Clifford Chance

News and awards

Clifford Chance advises DSM on proposed acquisition of Aland

16 July 2014

Clifford Chance advises DSM on proposed acquisition of Aland

Leading international law firm Clifford Chance has assisted Royal DSM on its signing of the share purchase agreement in relation to its proposed acquisition of Aland (HK) Holding Limited, a leading vitamin C manufacturer in China, based in Hong Kong. The closing of the transaction is subject to customary conditions.

This proposed transaction will further strengthen DSM's global position in the vitamin C market.

"We are very pleased to be working with DSM on this strategic transaction in Greater China", said Corporate partner Glen Ma, who led on this transaction. "We expect to see continuing significant M&A activity in the Healthcare and Life Sciences sector in the region, driven by industry consolidation and the attraction of Asia Pacific's population base."

On this transaction, Glen was supported by Emma Davies, a corporate partner based in Hong Kong and Shanghai, and assisted by Shanghai corporate counsel, Campbell Izzard, senior associate Bryan Koo, and associates Carolyn Huang and Janet Jiang in the Greater China offices, as well as colleagues Tony Reeves, Frances Dethmers and Heleen Engelen based in Brussels and Dimitri Slobodenjuk based in Dusseldorf on the antitrust elements of the transaction.

Royal DSM is a global science-based company active in health, nutrition and materials. Headquartered in the Netherlands, the company is listed on the NYSE Euronext exchange.